tiprankstipranks
Trending News
More News >

Keymed Biosciences Gains Approval for Stapokibart in Allergic Rhinitis Treatment

Story Highlights
Keymed Biosciences Gains Approval for Stapokibart in Allergic Rhinitis Treatment

Confident Investing Starts Here:

Keymed Biosciences, Inc. ( (HK:2162) ) just unveiled an update.

Keymed Biosciences, Inc. announced that China’s National Medical Products Administration has approved the supplemental New Drug Application for Stapokibart, a humanized antibody, for the treatment of seasonal allergic rhinitis. This approval is based on a successful phase III study showing Stapokibart’s efficacy and safety in controlling nasal and ocular symptoms. This development marks Stapokibart as the first domestically manufactured IL-4R α antibody drug granted marketing approval, which could enhance Keymed’s positioning in the biopharmaceutical market.

More about Keymed Biosciences, Inc.

Keymed Biosciences, Inc. is a company focused on the biotechnology industry, developing innovative therapeutic products. The company’s primary products include humanized antibodies targeting specific proteins involved in inflammatory processes, with a market focus on diseases such as atopic dermatitis and chronic rhinosinusitis.

YTD Price Performance: 2.43%

Average Trading Volume: 1,583,455

Technical Sentiment Consensus Rating: Buy

Current Market Cap: HK$8.28B

For a thorough assessment of 2162 stock, go to TipRanks’ Stock Analysis page.

Disclaimer & Disclosure

Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.

Report an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1